Organogenesis Announces Virtual Education Events for April
The virtual events will feature leading clinical experts and are designed to offer relevant, engaging and accessible educational content to clinicians and administrators in the advanced wound care and surgical markets during the current national health emergency.
“One way we can support our customers and other clinicians during this unprecedented time is to continue providing meaningful educational opportunities in virtual formats,” said
The Company will support the following virtual learning opportunities during the month of April.
Webinar – “The Use of an Amniotic Suspension Allograft for the Treatment of Symptomatic Knee Osteoarthritis”
On-Demand Webinar available on SportsMedinnovate.com. This physician education webinar, led by
Webinar – “PuraForce™ Tendon Reinforcement Matrix and NuShield® Sterilized, Dehydrated Placental Allograft for Foot and Ankle Tendon Repair”
This physician education webinar, led by
Webinar – “Management of Chronic Diabetic Foot Ulcers”
Part of the WoundSource Practice Accelerator series on Diabetic Foot Ulcers, sponsored by Organogenesis and Dermagraft® for the month of April. This webinar, led by Windy Cole, DPM, Director of
White Paper – “Diabetic Foot Ulcers: A Guide to Accepted Standard of Care for DFU”
Also part of the WoundSource Practice Accelerator series, this white paper will review the latest accepted standard of care for diabetic foot ulcers, including offloading options, wound bed preparation, glycemic control, debridement, patient education, and other important steps for DFU management. To download the white paper, click here.
Webinar – “NuCel® Amniotic Suspension Allograft for Lumbar Spine Fusion”
Sponsored by Organogenesis, this physician education webinar, led by
ReNu®, NuShield®, PuraForce™, NuCel® and Dermagraft® are products of Organogenesis.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” “continue” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include risks and uncertainties described in the Company’s filings with the
Press and Media Inquiries:
Susan Frodighsfrodigh@organo.com Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500
Source: Organogenesis Holdings Inc.